Akèy › Limfòm Non-Hodgkin › Utah
Etid klinik pou Limfòm Non-Hodgkin nan Utah
13 etid pou Limfòm Non-Hodgkin ap chèche patisipan nan sit nan Utah.
Vil nan Utah
Tèks ofisyèl etid la (Anglè)
A Study of LY4152199 in Participants With Previously Treated B-cell Malignancies (BAF_FRontier-1 )
- Intermountain Healthcare, Salt Lake City
Ap rekriteFaz 1
Laj 18 ak plis · Tout sèks · Mizajou Sep 22, 2026 · NCT07101328TAPUR: Testing the Use of Food and Drug Administration (FDA) Approved Drugs That Target a Specific Abnormality in a Tumor Gene in People With Advanced Stage Cancer
- Cedar City Hospital, SW Cancer Clinic, Sandra Maxwell Cancer Center, Cedar City
- Intermountain Healthcare, Salt Lake City
- Dixie Regional Medical Center-River Road Campus, St. George
Ap rekriteFaz 2
Laj 12 ak plis · Tout sèks · Mizajou Sep 22, 2026 · NCT02693535Study of Rondecabtagene Autoleucel in Aggressive Large B-Cell Lymphoma
- Huntsman Cancer Institute, Salt Lake City
- Intermountain Healthcare, Salt Lake City
Ap rekriteFaz 1/2
Laj 18 ak plis · Tout sèks · Mizajou Aug 25, 2026 · NCT05826535A Study to Investigate Ronde-cel Versus Investigator's Choice CD19 CAR T-Cell Therapy
- Intermountain Healthcare, Salt Lake City
Ap rekriteFaz 3
Laj 18 ak plis · Tout sèks · Mizajou Aug 4, 2026 · NCT07188558Immune Cell Therapy (CAR-T) for the Treatment of Patients With HIV and B-Cell Non-Hodgkin Lymphoma
- Huntsman Cancer Institute, University of Utah, Salt Lake City
Ap rekriteFaz 1
Laj 18 ak plis · Tout sèks · Mizajou Jul 10, 2026 · NCT05077527A Multicenter Access and Distribution Protocol for Unlicensed Cryopreserved Cord Blood Units (CBUs)
- University of Utah, Salt Lake City
Ap rekriteEtid obsèvasyon
Tout laj · Tout sèks · Mizajou Jul 6, 2026 · NCT01351545Study of Oral Administration of LP-118 in Patients With Relapsed or Refractory CLL, SLL, MDS, MDS/MPN, AML, CMML-2, MPN-BP, ALL, MF, NHL, RT, MM or T-PLL.
- University of Utah, Salt Lake City
Ap rekriteFaz 1
Laj 13 ak plis · Tout sèks · Mizajou May 5, 2026 · NCT04771572Trial to Evaluate the Safety & Tolerability of JBZ-001 in Pts With Advanced Solid and Hematological Malignancies
- START Mountain Region, West Valley City
Ap rekriteFaz 1
Laj 18 ak plis · Tout sèks · Mizajou Apr 24, 2026 · NCT06801002CA-4948-101: Open-Label, Dose Escalation and Expansion Trial of Emavusertib (CA-4948) in Relapsed or Refractory Primary Central Nervous System Lymphoma (R/R PCNSL)
- Huntsman Cancer Institute, University of Utah, Salt Lake City
Ap rekriteFaz 1/2
Laj 18 ak plis · Tout sèks · Mizajou Apr 16, 2026 · NCT03328078Transgene Assay Testing Service of Tumor Samples From Patients Who Received a Bristol-Myers Squibb Manufactured Gene Modified Cell Therapy and Have a Qualifying Second Primary Malignancy
- Huntsman Cancer Institute at the University of Utah, Salt Lake City
Ap rekriteEtid obsèvasyon
Tout laj · Tout sèks · Mizajou Jan 22, 2026 · NCT06357754A Safety and Efficacy Study Evaluating CTX112 in Subjects With Relapsed or Refractory B-Cell Malignancies
- University of Utah, Salt Lake City
Ap rekriteFaz 1/2
Laj 18 ak plis · Tout sèks · Mizajou Nov 14, 2025 · NCT05643742SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry
- Massive Bio SYNERGY-AI site, Salt Lake City
Ap rekriteEtid obsèvasyon
Tout laj · Tout sèks · Mizajou Oct 28, 2025 · NCT03452774ID Of Prognostic Factors In Mycosis Fungoides/Sezary Syndrome
- University of Utah Hospital, Salt Lake City
Ap rekriteEtid obsèvasyon
Tout laj · Tout sèks · Mizajou Oct 22, 2025 · NCT02848274Sous ClinicalTrials.gov, done yo ranmase Oct 1, 2026. Chak etid gen kritè li pou li menm; ekip etid la deside ki moun ki ka patisipe.